
KTTA Stock Forecast & Price Target
KTTA Analyst Ratings
Bulls say
Pasithea Therapeutics is well-positioned for success with strong potential for its drug candidates, particularly PAS-004 which may have broad utility beyond its initial target indications, and a favorable outlook for continued growth in the biotechnology sector. The company's solid balance sheet and progress in clinical trials make it a promising investment opportunity, with a promising Phase 1/1b study ongoing and expected data in the first quarter of 2026.
Bears say
Pasithea Therapeutics is a biotechnology company focused on developing treatments for CNS disorders and other diseases by leveraging their expertise in neuroscience, translational medicine, and drug development. Their current pipeline consists of three programs, with PAS-004 being their most promising project for treating RAS/RAF/NF1 mutated advanced solid tumors. However, there are potential risks associated with this program, as it is still in the early stages of clinical development and the company is being conservative in their market model approach, potentially limiting its potential upside. Additionally, there is strong competition in the MEK inhibitor market, with NFX-179 showing promising results for treating cutaneous NF1, potentially hindering Pasithea's market share in this area.
This aggregate rating is based on analysts' research of Pasithea Therapeutics Corp and is not a guaranteed prediction by Public.com or investment advice.
KTTA Analyst Forecast & Price Prediction
Start investing in KTTA
Order type
Buy in
Order amount
Est. shares
0 shares